Precigen, Inc. (NASDAQ:PGEN) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its holdings in shares of Precigen, Inc. (NASDAQ:PGEN - Free Report) by 18.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 884,275 shares of the biotechnology company's stock after selling 194,514 shares during the period. JPMorgan Chase & Co. owned 0.30% of Precigen worth $837,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. State Street Corp raised its holdings in Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company's stock valued at $2,720,000 after buying an additional 29,253 shares during the period. Iridian Asset Management LLC CT boosted its stake in Precigen by 82.5% in the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company's stock valued at $3,576,000 after acquiring an additional 1,706,815 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Precigen by 4.8% during the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock worth $3,075,000 after acquiring an additional 149,829 shares during the last quarter. Stifel Financial Corp increased its position in Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 15,680 shares during the period. Finally, Barclays PLC increased its stake in Precigen by 190.4% in the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company's stock valued at $179,000 after buying an additional 124,141 shares during the period. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on PGEN shares. JMP Securities reissued a "market outperform" rating and issued a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective (up previously from $4.00) on shares of Precigen in a research report on Thursday. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, Precigen currently has an average rating of "Hold" and a consensus price target of $7.00.

Precigen Price Performance

NASDAQ:PGEN traded down $0.09 during trading hours on Monday, reaching $1.30. 1,586,492 shares of the company were exchanged, compared to its average volume of 2,250,587. Precigen, Inc. has a 52-week low of $0.65 and a 52-week high of $1.93. The stock has a 50 day simple moving average of $0.95 and a 200 day simple moving average of $1.05. The firm has a market cap of $380.73 million, a price-to-earnings ratio of -2.36 and a beta of 1.65.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.